Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Ultragenyx Pharmaceu (RARE)

Ultragenyx Pharmaceu (RARE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,053,387
  • Shares Outstanding, K 96,630
  • Annual Sales, $ 673,000 K
  • Annual Income, $ -575,000 K
  • EBIT $ -535 M
  • EBITDA $ -504 M
  • 60-Month Beta 0.16
  • Price/Sales 3.08
  • Price/Cash Flow N/A
  • Price/Book N/A

Options Overview Details

View History
  • Implied Volatility 81.74% (+4.69%)
  • Historical Volatility 55.85%
  • IV Percentile 75%
  • IV Rank 29.48%
  • IV High 187.31% on 12/26/25
  • IV Low 37.62% on 09/11/25
  • Expected Move (DTE 11) 2.14 (9.47%)
  • Put/Call Vol Ratio 0.05
  • Today's Volume 251
  • Volume Avg (30-Day) 899
  • Put/Call OI Ratio 0.83
  • Today's Open Interest 19,686
  • Open Int (30-Day) 25,014
  • Expected Range 20.47 to 24.75

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 22 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate -1.48
  • Number of Estimates 9
  • High Estimate -1.06
  • Low Estimate -2.01
  • Prior Year -1.57
  • Growth Rate Est. (year over year) +5.73%

Price Performance

See More
Period Period Low Period High Performance
1-Month
19.60 +15.33%
on 02/13/26
24.68 -8.38%
on 02/10/26
-1.27 (-5.32%)
since 02/09/26
3-Month
18.41 +22.81%
on 12/29/25
36.81 -38.58%
on 12/15/25
-13.69 (-37.71%)
since 12/09/25
52-Week
18.41 +22.81%
on 12/29/25
42.37 -46.64%
on 07/09/25
-16.01 (-41.46%)
since 03/07/25

Most Recent Stories

More News
RARE Investors Have Opportunity to Lead Ultragenyx Pharmaceutical Inc. Securities Fraud Lawsuit

NEW YORK , March 9, 2026 /PRNewswire/ --

RARE : 22.61 (+6.40%)
RARE Investor Alert: Kessler Topaz Meltzer & Check, LLP Encourages RARE Investors with Losses to Contact the Firm

Did you buy RARE common stock between August 3, 2023, and December 26, 2025?

RARE : 22.61 (+6.40%)
Ultragenyx Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against Ultragenyx Pharmaceutical Inc. - RARE

NEW ORLEANS , March 6, 2026 /PRNewswire/ -- ClaimsFiler , a FREE shareholder information service, reminds investors that they have until April 6, 2026 to file lead plaintiff applications...

RARE : 22.61 (+6.40%)
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Ultragenyx Pharmaceutical Inc. of Class Action Lawsuit and Upcoming Deadlines - RARE

NEW YORK , March 5, 2026 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Ultragenyx Pharmaceutical Inc. ("Ultragenyx" or the "Company") (NASDAQ: RARE)....

RARE : 22.61 (+6.40%)
Ultragenyx Pharmaceutical Inc. Investors with Substantial Losses Have Opportunity to Lead Investor Class Action Lawsuit - RGRD Law

SAN DIEGO , March 4, 2026 /PRNewswire/ --  Robbins Geller Rudman & Dowd LLP announces purchasers or acquirers of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) common stock between August...

RARE : 22.61 (+6.40%)
LEVI & KORSINSKY, LLP: RARE STOCK DECLINED OVER 42% FOLLOWING PHASE III STUDY FAILURE DISCLOSURE

Alert: Claims Focus on Alleged Misrepresentations About Setrusumab Efficacy Potential

RARE : 22.61 (+6.40%)
RARE Investors Have Opportunity to Lead Ultragenyx Pharmaceutical Inc. Securities Fraud Lawsuit

NEW YORK , March 3, 2026 /PRNewswire/ --

RARE : 22.61 (+6.40%)
Shareholders that lost money on Ultragenyx Pharmaceutical Inc.(RARE) Urged to Join Class Action - Contact The Gross Law Firm to Learn More

NEW YORK , March 3, 2026 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE).

RARE : 22.61 (+6.40%)
Ultragenyx Pharmaceutical Inc. (RARE) Class Action Lawsuit Seeks Recovery for Investors; April 6, 2026, Deadline - Contact Kessler Topaz Meltzer & Check, LLP

Did you buy RARE common stock between August 3, 2023, and December 26, 2025?

RARE : 22.61 (+6.40%)
RARE Investors Have Opportunity to Lead Ultragenyx Pharmaceutical Inc. Securities Fraud Lawsuit with the Schall Law Firm

LOS ANGELES , March 2, 2026 /PRNewswire/ -- The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Ultragenyx Pharmaceutical...

RARE : 22.61 (+6.40%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Ultragenyx Pharmaceutical Inc. is focused on the identification, acquisition, development and commercialization of novel products for the treatment of rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases.

See More

Key Turning Points

3rd Resistance Point 24.60
2nd Resistance Point 23.70
1st Resistance Point 23.16
Last Price 22.61
1st Support Level 21.72
2nd Support Level 20.82
3rd Support Level 20.28

See More

52-Week High 42.37
Fibonacci 61.8% 33.22
Fibonacci 50% 30.39
Fibonacci 38.2% 27.56
Last Price 22.61
52-Week Low 18.41

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar